Read news on mutated NSCLC with our app.
Read more in the app
Eight-year ADAURA update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated NSCLC
Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds - EurekAlert!
HER2-mutated NSCLC in Brazil shows diverse genetic patterns and treatment gaps - EurekAlert!
